COVID protocols - one-way system; face coverings; sanitising
Fire safety / First aid
Mobile phones
Q&A session - microphones if required
Demonstration area
Agenda
10:00
Welcome and Business review
10:20
AGM - formal business, including question and answer session with
Renishaw Board
c.11:00
Close meeting
Business review and Trading update
Will Lee, Chief Executive
Summary
Revenue growth of 11% to £565.6m
Positive year of recovery
Strong growth in APAC throughout the year, improving sales in EMEA and Americas in H2
Adjusted profit before tax up by 146% to £119.7m
Fit for the Future initiative reduced our cost base and drove productivity improvements
Return on sales increased to 21% (2020: 10%), with 25% in H2
End of period cash rises to £215.0m
Strong trading performance and reduced capital expenditure and dividends
Formal sale process, which commenced in March 2021, was concluded in July with no suitable offers
Key metrics
2021
2020
Change
£m
£m
%
Revenue
565.6
510.2
11%
Adjusted profit
119.7
48.6
146%
before tax
Statutory profit
139.4
3.2
4,256%
before tax
End of period cash
215.0
120.4
and bank deposits
Regional revenue
2021
2020
Change
£m
£m
%
APAC
274.8
227.7
21%
EMEA
169.1
167.2
1%
Americas
121.7
115.3
5%
Slide 4
Transforming Tomorrow Together
We make it possible to create the products, materials and therapies that will
define our world in the decades to come and touch billions of lives
Manufacturing technologies
Analytical instruments and medical devices
(formerly Metrology)
(formerly Healthcare)
Slide 5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Renishaw plc published this content on 14 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2021 08:48:03 UTC.
Renishaw plc is a United Kingdom-based supplier of measuring systems and production systems. The principal activities of the Company are the design, manufacture, sale, distribution and service of manufacturing technologies products and services, and analytical instruments and medical devices. The Company operates through two segments: manufacturing technologies, and analytical instruments and medical devices. The manufacturing technologies segment consists of four areas: industrial metrology, additive manufacturing, position measurement and the new industrial automation line. The analytical instruments and medical devices segment consist of spectroscopy and neurological, where it supplies its customers with technologies to improve materials analysis and neurological therapies. Its products include CMM probes, software, and retrofits; equator gauging system; interferometric laser encoders; probing and tool measurement systems for machine tools, and others.
RENISHAW PLC 
